Skip to main content
Top
Published in: Drugs & Aging 9/2010

01-09-2010 | Original Research Article

Risk of Potential Drug-Drug Interactions among Brazilian Elderly

A Population-Based, Cross-Sectional Study

Authors: Silvia-Regina Secoli, Dr Albert Figueras, Maria Lúcia Lebrão, Fernão Dias de Lima, Jair Licio Ferreira Santos

Published in: Drugs & Aging | Issue 9/2010

Login to get access

Abstract

Background Drug-drug interactions (DDIs) are one of the main causes of adverse reactions related to medications, being responsible for up to 23% of hospital admissions. However, only a few studies have evaluated this problem in elderly Brazilians.
Objectives To determine the prevalence of potential DDIs (PDDIs) in community-dwelling elderly people in Brazil, analyse these interactions with regard to severity and clinical implications, and identify associated factors.
Methods A population-based cross-sectional study was carried out involving 2143 elderly (aged ≥60 years) residents of the metropolitan area of Sao Paulo, Brazil. Data were obtained from the SABE (Saúde, Bem estar e Envelhecimento [Health, Well-Being, and Aging]) survey, which is a multicentre study carried out in seven countries of Latin America and the Caribbean, coordinated by the Pan-American Health Organization. PDDIs were analysed using a computerized program and categorized according to level of severity, onset, mechanism and documentation in the literature. The STATA software statistical package was used for data analysis, and logistic regression was conducted to determine whether variables were associated with PDDIs.
Results Analysis revealed that 568 (26.5%) of the elderly population included in the study were taking medications that could lead to a DDI. Almost two-thirds (64.4%) of the elderly population exposed to PDDIs were women, 50.7% were aged ≥75 years, 71.7% reported having fair or poor health and 65.8% took 2–5 medications. A total of 125 different PDDIs were identified; the treatment combination of an ACE inhibitor with a thiazide or loop diuretic (associated with hypotension) was the most frequent cause of PDDIs (n=322 patients; 56.7% of individuals with PDDIs). Analysis of the PDDIs revealed that 70.4% were of moderate severity, 64.8% were supported by good quality evidence and 56.8% were considered of delayed onset. The multivariate analysis showed that the risk of a PDDI was significantly increased among elderly individuals using six or more medications (odds ratio [OR] 3.37) and in patients with hypertension (OR 2.56), diabetes mellitus (OR 1.73) or heart problems (OR 3.36).
Conclusions Approximately one-quarter of the elderly population living in Sao Paulo could be taking two or more potentially interacting medicines. Polypharmacy predisposes elderly individuals to PDDIs. More than half of these drug combinations (57.6%, n=72) were part of commonly employed treatment regimens and may be responsible for adverse reactions that compromise the safety of elderly individuals, especially at home. Educational initiatives are needed to avoid unnecessary risks.
Literature
1.
go back to reference Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993; 27: 832–9PubMed Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993; 27: 832–9PubMed
2.
go back to reference Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. JAMA 1997; 277: 301–6PubMedCrossRef Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. JAMA 1997; 277: 301–6PubMedCrossRef
3.
go back to reference Hohl CM, Dankoff J, Colacone A, et al. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 2001; 38: 666–71PubMedCrossRef Hohl CM, Dankoff J, Colacone A, et al. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 2001; 38: 666–71PubMedCrossRef
4.
go back to reference Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 200–5CrossRef Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 200–5CrossRef
5.
go back to reference Tato DS. Drug interactions facts. Saint Louis (MO): Facts and Comparisons, 2002 Tato DS. Drug interactions facts. Saint Louis (MO): Facts and Comparisons, 2002
6.
go back to reference Bachmann KA. Drug interactions handbook. Hudson (OH): Lexi, 2003 Bachmann KA. Drug interactions handbook. Hudson (OH): Lexi, 2003
7.
go back to reference Grahame-Smith DG, Aronson JK. Drug interactions. In: Grahame-Smith DG, Aronson JK. Oxford textbook of clinical pharmacology and drug therapy. Oxford: Oxford University Press, 2002: 105–18 Grahame-Smith DG, Aronson JK. Drug interactions. In: Grahame-Smith DG, Aronson JK. Oxford textbook of clinical pharmacology and drug therapy. Oxford: Oxford University Press, 2002: 105–18
8.
go back to reference Secoli SR. Drug interactions: fundamental aspects for clinical practice nursing. Rev Esc Enferm USP 2001; 35: 28–34CrossRef Secoli SR. Drug interactions: fundamental aspects for clinical practice nursing. Rev Esc Enferm USP 2001; 35: 28–34CrossRef
9.
go back to reference Fonseca RB, Secoli SR. Drugs used in bone marrow transplantation: a study about combinations of antimicrobial potentially interactives. Rev Esc Enferm USP 2008; 42: 706–14PubMedCrossRef Fonseca RB, Secoli SR. Drugs used in bone marrow transplantation: a study about combinations of antimicrobial potentially interactives. Rev Esc Enferm USP 2008; 42: 706–14PubMedCrossRef
10.
go back to reference Spitzer WO. Drug as determinants of health and disease in the population: an orientation to the bridge of pharmacoepidemiology. J Clin Epidemiol 1991; 44: 823–30PubMedCrossRef Spitzer WO. Drug as determinants of health and disease in the population: an orientation to the bridge of pharmacoepidemiology. J Clin Epidemiol 1991; 44: 823–30PubMedCrossRef
11.
go back to reference Prybys KM, Melville K, Hanna J, et al. Polypharmacy in the elderly — clinical challenges in emergency practice: part 1. Overview, etiology, and drug interactions. Emerg Med Rep 2002; 23: 145–53 Prybys KM, Melville K, Hanna J, et al. Polypharmacy in the elderly — clinical challenges in emergency practice: part 1. Overview, etiology, and drug interactions. Emerg Med Rep 2002; 23: 145–53
12.
go back to reference Bjorkman IK, Fastbom J, Schmidt IK, et al., The Pharmaceutical Care of the Elderly in Europe Research (PEER) Group. Drug-drug interactions in the elderly. Ann Pharmacother 2002; 36: 1675–81PubMedCrossRef Bjorkman IK, Fastbom J, Schmidt IK, et al., The Pharmaceutical Care of the Elderly in Europe Research (PEER) Group. Drug-drug interactions in the elderly. Ann Pharmacother 2002; 36: 1675–81PubMedCrossRef
13.
go back to reference Passarelli MC, Jacob-Filho W, Figueras A. Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging 2005; 22: 767–77PubMedCrossRef Passarelli MC, Jacob-Filho W, Figueras A. Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging 2005; 22: 767–77PubMedCrossRef
14.
go back to reference Egger SS, Jurgen D, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 2004; 58: 773–8 Egger SS, Jurgen D, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 2004; 58: 773–8
15.
go back to reference Schneider JK, Mion LC, Frengley JD. Adverse drug reactions in an elderly outpatient population. Am J Hosp Pharm 1992; 49: 90–6PubMed Schneider JK, Mion LC, Frengley JD. Adverse drug reactions in an elderly outpatient population. Am J Hosp Pharm 1992; 49: 90–6PubMed
16.
go back to reference McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002; 36: 1331–6PubMedCrossRef McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002; 36: 1331–6PubMedCrossRef
17.
go back to reference Langdorf M, Fox J, Marwah R, et al. Physician versus computer knowledge of potential drug interactions in the emergency department. Acad Emerg Med 2000; 7: 1321–9PubMedCrossRef Langdorf M, Fox J, Marwah R, et al. Physician versus computer knowledge of potential drug interactions in the emergency department. Acad Emerg Med 2000; 7: 1321–9PubMedCrossRef
18.
go back to reference Gaddi G, Holt T, Woods M. Drug interactions in at risk emergency department patients. Acad Emerg Med 2002; 9: 1162–7CrossRef Gaddi G, Holt T, Woods M. Drug interactions in at risk emergency department patients. Acad Emerg Med 2002; 9: 1162–7CrossRef
19.
go back to reference Doucet J, Chassagne P, Trivalle C, et al. Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatric Soc 1996; 44: 944–8 Doucet J, Chassagne P, Trivalle C, et al. Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatric Soc 1996; 44: 944–8
20.
go back to reference Bootman JL, Harrison DL, Cox E. The health care cost of drug-related morbidity and mortality in nursing facilities. Arch Intern Med 1997; 157: 2089–96PubMedCrossRef Bootman JL, Harrison DL, Cox E. The health care cost of drug-related morbidity and mortality in nursing facilities. Arch Intern Med 1997; 157: 2089–96PubMedCrossRef
21.
go back to reference Lebrão ML, Laurenti R. Health, well-being and aging: the SABE study in São Paulo, Brazil. Rev Bras Epidemiol 2005; 8: 127–41CrossRef Lebrão ML, Laurenti R. Health, well-being and aging: the SABE study in São Paulo, Brazil. Rev Bras Epidemiol 2005; 8: 127–41CrossRef
22.
go back to reference World Health Organization. Anatomical therapeutic chemical (ATC) classification index with defined daily doses (DDDs); Geneva, 2007 (updated on 2006 Dec 16) [online]. Available from URL: http://www.whocc.no/atcddd/index [Accessed 2007 Mar 16] World Health Organization. Anatomical therapeutic chemical (ATC) classification index with defined daily doses (DDDs); Geneva, 2007 (updated on 2006 Dec 16) [online]. Available from URL: http://​www.​whocc.​no/​atcddd/​index [Accessed 2007 Mar 16]
23.
24.
go back to reference Costa AJ. Potential drug interactions in an ambulatory geriatric population. Fam Pract 1991; 8: 234–6PubMedCrossRef Costa AJ. Potential drug interactions in an ambulatory geriatric population. Fam Pract 1991; 8: 234–6PubMedCrossRef
25.
go back to reference Bergendal L, Friberg A, Schaffrath AM. Potential drug-drug interactions in 5,125 mostly elderly out-patients in Gothenburg, Sweden. Pharm World Sci 1995; 17: 152–7PubMedCrossRef Bergendal L, Friberg A, Schaffrath AM. Potential drug-drug interactions in 5,125 mostly elderly out-patients in Gothenburg, Sweden. Pharm World Sci 1995; 17: 152–7PubMedCrossRef
26.
go back to reference Gaeta TJ, Fiorini M, Ender K, et al. Potential drug-drug interactions in elderly patients presenting with syncope. J Emerg Med 2002; 22: 159–62PubMedCrossRef Gaeta TJ, Fiorini M, Ender K, et al. Potential drug-drug interactions in elderly patients presenting with syncope. J Emerg Med 2002; 22: 159–62PubMedCrossRef
27.
go back to reference Aparasu R, Baer R, Aparasu A. Clinically important potential drug-drug interactions in outpatient settings. Res Soc Administrat Pharm 2007; 3: 426–37CrossRef Aparasu R, Baer R, Aparasu A. Clinically important potential drug-drug interactions in outpatient settings. Res Soc Administrat Pharm 2007; 3: 426–37CrossRef
28.
go back to reference Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol 2003; 48: 133–43PubMedCrossRef Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol 2003; 48: 133–43PubMedCrossRef
30.
go back to reference Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med 1995; 155: 1949–56PubMedCrossRef Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med 1995; 155: 1949–56PubMedCrossRef
31.
go back to reference Thomas A, Routledge PA. Drug interaction in clinical practice. Focus Pharmacovigilance Bull 2003: 1–7 Thomas A, Routledge PA. Drug interaction in clinical practice. Focus Pharmacovigilance Bull 2003: 1–7
32.
go back to reference Seymour RM, Routledge PA. Important drug-drug interactions the elderly. Drugs Aging 1998; 12: 485–94PubMedCrossRef Seymour RM, Routledge PA. Important drug-drug interactions the elderly. Drugs Aging 1998; 12: 485–94PubMedCrossRef
33.
34.
go back to reference Ament PW, Bertolino JG, Liszewski JL. Clinically significant drug interactions. Am Fam Physician 2000; 61: 1745–54PubMed Ament PW, Bertolino JG, Liszewski JL. Clinically significant drug interactions. Am Fam Physician 2000; 61: 1745–54PubMed
35.
go back to reference Oscanoa T. Interaction medicamentosa em geriatría. An Facultad Medic 2006; 2: 119–26 Oscanoa T. Interaction medicamentosa em geriatría. An Facultad Medic 2006; 2: 119–26
36.
go back to reference Romero R, Castellote E, Ocon J, et al. Controlled multi-center study with quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension. J Cardiovasc Pharmacol 1995; 26: 114–8PubMedCrossRef Romero R, Castellote E, Ocon J, et al. Controlled multi-center study with quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension. J Cardiovasc Pharmacol 1995; 26: 114–8PubMedCrossRef
37.
go back to reference Mahe I, Meune C, Diemer M, et al. Interaction between aspirin and ACE inhibitors in patients with heart failure. Drug Saf 2001; 24: 167–82PubMedCrossRef Mahe I, Meune C, Diemer M, et al. Interaction between aspirin and ACE inhibitors in patients with heart failure. Drug Saf 2001; 24: 167–82PubMedCrossRef
38.
go back to reference Malone DC, Hutchins DS, Haupert H, et al. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm 2005; 62: 1983–91PubMedCrossRef Malone DC, Hutchins DS, Haupert H, et al. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm 2005; 62: 1983–91PubMedCrossRef
39.
go back to reference Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095–106PubMedCrossRef Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095–106PubMedCrossRef
40.
go back to reference Chung L, Chakravarty EF, Kearns P, et al. Bleeding complications in patients on celecoxib and warfarin. J Clin Pharm Ther 2005; 30: 471–7PubMedCrossRef Chung L, Chakravarty EF, Kearns P, et al. Bleeding complications in patients on celecoxib and warfarin. J Clin Pharm Ther 2005; 30: 471–7PubMedCrossRef
41.
go back to reference Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289: 1652–8PubMedCrossRef Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289: 1652–8PubMedCrossRef
42.
go back to reference Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 2007; 370: 185–91PubMedCrossRef Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 2007; 370: 185–91PubMedCrossRef
Metadata
Title
Risk of Potential Drug-Drug Interactions among Brazilian Elderly
A Population-Based, Cross-Sectional Study
Authors
Silvia-Regina Secoli
Dr Albert Figueras
Maria Lúcia Lebrão
Fernão Dias de Lima
Jair Licio Ferreira Santos
Publication date
01-09-2010
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 9/2010
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/11538460-000000000-00000

Other articles of this Issue 9/2010

Drugs & Aging 9/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.